Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services has informed the stock exchanges that its subsidiary, Optival Health Solutions Private Limited, received two drug license suspension orders from the Drugs Control Administration in Davanagere, Karnataka. The first order suspends the license of a store at Vinobha Nagar for 5 days, while the second suspends the license of a store at KSRTC Davanagere for 7 days. Both suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The combined potential revenue impact from these two stores is approximately Rs 4.19 lakhs (Rs 1.40 lakhs + Rs 2.79 lakhs). The orders were received on February 20, 2026.
The financial impact is negligible — only about Rs 4.19 lakhs in potential revenue loss across two stores out of Medplus's large retail network. This appears to be a routine regulatory compliance matter and is unlikely to have any meaningful effect on the stock price or overall business.